Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

BioAge just completed its IPO to continue funding clinical trials, but competition will be stiff. BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

BioAge Labs is a new kid on the block. The company completed its initial public offering (IPO) on Oct. 1. The biotech's leading candidate is called azelaprag. It is being developed as a weight ...

Recent strong debuts by weight-loss drug developer BioAge Labs and TPG-backed cancer ... in the sector and encouraged listings among other IPO candidates. Bengaluru: TPG-backed CeriBell is ...

BioAge Labs raised $238.3 million in its IPO. Moreover, the company's S-1 Filing shows that operating expenses were $28.1 million through the first six months of 2024 -- implying an annual run ...

Well, a little-known biopharmaceutical company called BioAge Labs (NASDAQ: BIOA) is looking to bring a new spin to the weight loss space, and it just completed its initial public offering (IPO).

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

This page features the latest news about the Bioage Labs stock. BioAge Labs director Enright buys $7.2 million in stock BioAge Labs, Inc. (NASDAQ:BIOA) has seen significant insider activity as ...